These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38510991)

  • 1. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma.
    Mellgard G; Gilligan M; Cliff ERS; Bhutani D; Mohyuddin GR; Eisenberger A; Lentzsch S; Chakraborty R
    Hemasphere; 2024 Mar; 8(3):e61. PubMed ID: 38510991
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
    Lussier T; Schoebe N; Mai S
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.
    Wennmann M; Kintzelé L; Piraud M; Menze BH; Hielscher T; Hofmanninger J; Wagner B; Kauczor HU; Merz M; Hillengass J; Langs G; Weber MA
    Oncotarget; 2018 May; 9(38):25254-25264. PubMed ID: 29861868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
    Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
    Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
    Kunacheewa C; Manasanch EE
    Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Early Intervention in High-Risk Smoldering Myeloma.
    Joseph NS; Dhodapkar MV; Lonial S
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
    Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
    Bustoros M; Anand S; Sklavenitis-Pistofidis R; Redd R; Boyle EM; Zhitomirsky B; Dunford AJ; Tai YT; Chavda SJ; Boehner C; Neuse CJ; Rahmat M; Dutta A; Casneuf T; Verona R; Kastritis E; Trippa L; Stewart C; Walker BA; Davies FE; Dimopoulos MA; Bergsagel PL; Yong K; Morgan GJ; Aguet F; Getz G; Ghobrial IM
    Nat Commun; 2022 Jun; 13(1):3449. PubMed ID: 35705541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The consultant's guide to smoldering multiple myeloma.
    Thorsteinsdottir S; Kristinsson SY
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
    Termini R; Žihala D; Terpos E; Perez-Montaña A; Jelínek T; Raab M; Weinhold N; Mai EK; Grab AL; Corre J; Vergez F; Sacco A; Chiarini M; Giustini V; Tucci A; Rodriguez S; Moreno C; Perez C; Maia C; Martín-Sánchez E; Guerrero C; Botta C; Garces JJ; Lopez A; Tamariz-Amador LE; Prosper F; Bargay J; Cabezudo ME; Ocio EM; Hájek R; Martinez-Lopez J; Solano F; Iglesias R; Paiva A; Geraldes C; Vitoria H; Gomez C; De Arriba F; Ludwig H; Garcia-Guiñon A; Casanova M; Alegre A; Cabañas V; Sirvent M; Oriol A; de la Rubia J; Hernández-Rivas JÁ; Palomera L; Sarasa M; Rios P; Puig N; Mateos MV; Flores-Montero J; Orfao A; Goldschmidt H; Avet-Loiseau H; Roccaro AM; San-Miguel JF; Paiva B;
    Clin Cancer Res; 2022 Nov; 28(21):4771-4781. PubMed ID: 36074126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding high-risk smoldering multiple myeloma.
    Kreiniz N; Gertz MA
    Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
    Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
    Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering multiple myeloma - Past, present, and future.
    Mann H; Katiyar V; Varga C; Comenzo RL
    Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions.
    Blum A; Bazou D; O'Gorman P
    Blood Lymphat Cancer; 2018; 8():21-31. PubMed ID: 31360091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.